What Paxlovid Does and Its Adverse Reactions
Paxlovid (nirmatrelvir/ritonavir) significantly reduces hospitalizations and mortality in COVID-19 patients at high risk of disease progression when started within 5 days of symptom onset, with the most common adverse reactions being dysgeusia (altered taste) and diarrhea. 1, 2, 3
Mechanism and Clinical Benefits
Paxlovid combines nirmatrelvir (a SARS-CoV-2 main protease inhibitor) with ritonavir (which inhibits nirmatrelvir's metabolism to maintain therapeutic drug levels). The combination provides high certainty evidence of important reductions in hospitalization risk and moderate certainty of survival benefit without increasing adverse effects leading to drug discontinuation. 1
Key Clinical Effects:
- Reduces hospitalizations in high-risk patients with non-severe COVID-19 (strong recommendation) 1
- Reduces mortality (moderate certainty evidence) 1
- Accelerates viral clearance - significantly increases cycle threshold values of viral genes after treatment 4
- Does NOT significantly impact time to symptom resolution (low certainty evidence) 1
Adverse Reactions
Common Adverse Reactions (≥1% incidence, more than placebo):
- Dysgeusia (altered/loss of taste) - most frequently reported, significantly higher with Paxlovid 1, 2, 3, 5
- Diarrhea 1, 2, 3
Serious but Less Common Reactions:
- Hypersensitivity reactions including anaphylaxis, toxic epidermal necrolysis, and Stevens-Johnson syndrome 2, 3
- Hepatotoxicity - hepatic transaminase elevations, clinical hepatitis, and jaundice (from ritonavir component) 2, 3
Neurological Adverse Events:
Recent real-world data shows Paxlovid has a 2.27-fold higher signal for neurological adverse reactions compared to other COVID-19 drugs, with particular attention needed for 6:
- Dysgeusia and ageusia (loss of taste)
- Headache (not commonly mentioned in prescribing information but occurs in practice)
- Anosmia (loss of smell - also underreported in official labeling)
Female patients within the first 30 days of treatment require special monitoring for these neurological symptoms. 6
Critical Safety Considerations
Drug-Drug Interactions - The Major Pitfall
Ritonavir is a potent CYP3A4 inhibitor causing extensive drug interactions that can be life-threatening. 1, 2, 3 This is the most important practical limitation of Paxlovid use.
Contraindicated medications (cannot be used with Paxlovid) include:
- Alfuzosin, silodosin
- Amiodarone, dronedarone, flecainide, propafenone, quinidine
- Lovastatin, simvastatin (can be temporarily stopped)
- Triazolam, oral midazolam
- Ergot derivatives
- Pimozide, lurasidone
- Ranolazine
- Sildenafil for pulmonary arterial hypertension
- Strong CYP3A inducers: rifampin, carbamazepine, phenytoin, St. John's Wort 2, 3
In long-term care facilities, 86% of residents had at least one potential drug interaction, most commonly with atorvastatin (28%), amlodipine (22%), and apixaban (16%). 7 Always check the Liverpool COVID-19 drug interaction tool before prescribing. 1
Renal Impairment Dosing
- eGFR 30-59 mL/min: Reduce to 150 mg nirmatrelvir/100 mg ritonavir twice daily 1, 2, 3
- eGFR <30 mL/min: Not recommended (per updated 2025 FDA label) or use reduced dosing with extreme caution 2
Hepatic Impairment
Not recommended in severe hepatic impairment (Child-Pugh Class C) 1, 2, 3
Special Populations
- Pregnancy/breastfeeding: Can be considered as an option to reduce disease progression risk, with no serious adverse reactions reported in WHO Vigibase to date, though uncertainty remains 1
- HIV patients: Risk of developing HIV-1 protease inhibitor resistance in uncontrolled/undiagnosed HIV infection 2, 3
Practical Administration
Dosing: 300 mg nirmatrelvir (two 150 mg tablets) + 100 mg ritonavir (one 100 mg tablet) taken together twice daily for 5 days 1, 2, 3
Timing: Must be started within 5 days of symptom onset for optimal benefit 1, 2, 3
Administration: Can be taken with or without food, at approximately the same time each day 2
Tolerability Profile
High certainty evidence shows no effect on adverse effects leading to drug discontinuation, indicating good overall tolerability despite the taste disturbances. 1 Real-world studies confirm positive safety profiles with no significant differences in neurological disease, liver injury, or kidney injury rates compared to standard dosing groups. 4
Paxlovid represents the superior antiviral choice over molnupiravir (greater efficacy, safety concerns with molnupiravir) and remdesivir (requires IV administration), provided drug interactions can be appropriately managed. 1, 8